Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 8, Issue 5, 2007, Pages 313-318

  Wozniak, Antoinette J ^a,d   Belzer, Kimberly ^a   Heilbrun, Lance K ^a   Kucuk, Omer ^a   Gadgeel, Shirish ^a   Kalemkerian, Gregory P ^b   Venkatramanamoorthy, Raghu ^a   Kraut, Michael J ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c Providence Cancer Center   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Overall survival; Time to progression

Indexed keywords

ANTIEMETIC AGENT; DIPHENHYDRAMINE; GEMCITABINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL; STEROID;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 34248170111     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2007.n.010     Document Type: Article

References (22)

1. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18:623-631.
2. Sandler AB, Nemunaitis C, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000; 18:122-130.
3. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16:2459-2465.
4. Schiller JH, Harrington D, Sandler A, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346:92-98.
5. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85:384-388.
6. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1535-1540.
7. Einhorn L, Raghavan D, Kindler H, et al. A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors. Proc Am Soc Clin Oncol 1998; 17:207a (Abstract #796).
8. Bhatia S, Hanna N, Ansari R, et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 2002; 38:73-77.
9. De Pas T, de Braud F, Danesi R, et al. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. Ann Oncol 2000; 11:821-827.
10. Giaccone G, Smit EF, van Meerbeeck JP, et al. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. Ann Oncol 2000; 11:109-112.
11. Rothenberg ML, Sharman A, Weiss GR, et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 1998; 9:733-738.
12. Casella G. Refining binomial confidence intervals. Can J Stat 1987; 14:113-129.
13. StatXact 5: Statistical software for exact nonparametric inference [user manual]. Cytel Software Corporation, 1999.
14. Lee E. Statistical Methods for Survival Data Analysis. 2nd ed. Hoboken, NJ: Wiley & Sons, Inc. 1992:77-78.
15. Douillard JY, Lerouge D, Monnier A, et al. Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study. Br J Cancer 2001; 84:1179-1184.
16. Isla D, Rosell R, Sanchez JJ, et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2001; 19:1071-1077.
17. Kakolyris S, Georgoulias V. The role of gemcitabine and paclitaxel as second-line chemotherapy for the treatment of advanced non small-cell lung cancer (NSCLC). Clin Lung Cancer 2000; 2:43-47.
18. Dongiovanni V, Addeo A, Berruti A, et al. A phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbine. Anticancer Res 2004; 24:2567-2572.
19. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer lung cancer group-EORTC 08975. J Clin Oncol 2003; 21:3909-3917.
20. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002; 20:3578-3585.
21. Treat J, Belani CP, Edelman MA, et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC): update of the Alpha Oncology trial (A1-99002L). J Clin Oncol 2005; 23(16 suppl): 1096s (Abstract #LBA7025).
22. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-353.